0 code page views remaining today. Guest accounts are limited to 2 daily page views. Register free account to get more views.
Log in Register free account

Official Description

Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection

© Copyright 2025 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 96381 refers to the administration of a seasonal dose of respiratory syncytial virus (RSV) monoclonal antibody via intramuscular injection. This procedure involves delivering a vaccine that contains laboratory-produced proteins designed to mimic the immune response against the RSV virus, which is known to cause severe respiratory infections, particularly in infants and young children. The administration is typically performed as a single intramuscular injection into the anterolateral thigh, a common site for such vaccinations. This procedure is crucial for infants and neonates entering their first RSV season, as well as for young children under the age of two who remain highly susceptible to the virus. The timing of the administration is generally scheduled for October or November, aligning with the onset of the RSV season to provide optimal protection. Additionally, it is important to note that the administration of this vaccine may include face-to-face counseling provided by a physician or qualified healthcare professional to the patient’s family or caregiver, as indicated by the related code 96380.

© Copyright 2025 Coding Ahead. All rights reserved.

1. Indications

The administration of the respiratory syncytial virus (RSV) monoclonal antibody is indicated for specific patient populations who are at high risk for severe RSV disease. The following conditions warrant the use of this procedure:

  • Infants and Neonates: This procedure is indicated for infants and neonates who are entering their first RSV season, as they are particularly vulnerable to severe respiratory infections caused by RSV.
  • Young Children Under Two Years: The procedure is also indicated for young children under the age of two who remain susceptible to RSV, especially those with underlying health conditions that may increase their risk of severe disease.

2. Procedure

The procedure for administering the RSV monoclonal antibody involves several key steps to ensure proper delivery and patient safety. Each step is critical to the successful administration of the vaccine:

  • Step 1: Preparation of the Vaccine The healthcare provider prepares the RSV monoclonal antibody vaccine according to the manufacturer's guidelines. This includes checking the expiration date, ensuring the vaccine is stored at the correct temperature, and drawing the appropriate dose into a syringe.
  • Step 2: Patient Identification and Consent The healthcare provider verifies the patient's identity and confirms that the patient meets the criteria for receiving the vaccine. Informed consent is obtained from the patient’s parent or guardian, explaining the benefits and potential risks associated with the vaccine.
  • Step 3: Administration of the Injection The vaccine is administered as a single intramuscular injection into the anterolateral thigh. The provider cleans the injection site with an antiseptic wipe to reduce the risk of infection and uses a sterile needle to deliver the vaccine. Proper technique is employed to ensure the injection is given safely and effectively.
  • Step 4: Post-Administration Monitoring After the injection, the patient is monitored for a short period to observe for any immediate adverse reactions. This is a standard practice to ensure patient safety following vaccination.

3. Post-Procedure

Post-procedure care following the administration of the RSV monoclonal antibody includes monitoring the patient for any immediate side effects or allergic reactions. Patients may experience mild side effects such as soreness at the injection site, low-grade fever, or irritability, which typically resolve on their own. Parents or caregivers are advised to observe the patient for any unusual symptoms and to contact a healthcare provider if they have concerns. Additionally, follow-up appointments may be scheduled to assess the patient's response to the vaccine and to discuss any further vaccinations or health considerations as the RSV season progresses.

Short Descr ADMN RSV MONOC ANTB IM NJX
Medium Descr ADMN RSV MONOCLONAL ANTB SEASONAL DOSE IM NJX
Long Descr Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection
Status Code Active Code
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 0 - Physician Service Code
Multiple Procedures (51) 0 - No payment adjustment rules for multiple procedures apply.
Bilateral Surgery (50) 0 - 150% payment adjustment for bilateral procedures does NOT apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 0 - Payment restriction for assistants at surgery applies to this procedure...
Co-Surgeons (62) 0 - Co-surgeons not permitted for this procedure.
Team Surgery (66) 0 - Team surgeons not permitted for this procedure.
Diagnostic Imaging Family 99 - Concept Does Not Apply
APC Status Indicator Items and Services Not Billable to the MAC
Berenson-Eggers TOS (BETOS) none
MUE 1
96 Habilitative services: when a service or procedure that may be either habilitative or rehabilitative in nature is provided for habilitative purposes, the physician or other qualified health care professional may add modifier 96 to the service or procedure code to indicate that the service or procedure provided was a habilitative service. habilitative services help an individual learn skills and functioning for daily living that the individual has not yet developed, and then keep and/or improve those learned skills. habilitative services also help an individual keep, learn, or improve skills and functioning for daily living.
GA Waiver of liability statement issued as required by payer policy, individual case
GW Service not related to the hospice patient's terminal condition
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
GZ Item or service expected to be denied as not reasonable and necessary
SL State supplied vaccine
Date
Action
Notes
2025-01-01 Added First appearance in codebook
2023-10-06 Added Code added.
2023-10-06 Note AMA guideline includes 90380 & 90381: Published on AMA website & received FDA approval prior to the addition of 96380.
Code
Description